

treatments

weeks





PHYSICIAN ORDER SET:


# **GOLIMUMAB LOAD (SCHEDULE WEEKS 0,4)**

CDH 208-261 - Approved - Page 1 of 5

| Patie         | nt:  | DOB:  |  | Gender:  |   |
|---------------|--|---|--|--|---|
| Patie         | nt Phone #:  | Height:   |  | Weight:  |   |
| Diagr         | nosis:   | ICD-10 Code:  |  |  |   |
| Treat         | ment Start Date:   |   |  |  |   |
| Provi         | der Facility Name:   | Provider Facility   | y Address: _   |  |   |
| Orde          | ring Provider:   | Date:   |  |  |   |
| Signa         | ature:   |   |  |  |   |
|               | **Please include H&P/ current medications list/ allerg  For Blood Transfusions. please ens   | ies, and ensure that m  | ed authorization   | ons have been obta                             | nined**   |
| Criter        |  | ies, and ensure that m  | ed authorization   | ons have been obta                             |   |
| <u>Criter</u> | **Please include H&P/ current medications list/ allerg   | ies, and ensure that m  | ed authorization<br>of has been obto<br>Interval<br>Every 4  | ons have been obta                             | <b>Duration</b> Until                           |
|               | **Please include H&P/ current medications list/ allerg  For Blood Transfusions, please ens  ia to Treat  Criteria to Treat  Verify that the patient has: 1) a negative hepatitis B screen of treatment 3) not received a live vaccine within the last 4 weed documentation that it is okay to proceed with infusion. If doc  | ies, and ensure that mure that signed consertion  Dose  or is hepatitis B immune 2 eks. If any of these criteria                            | ed authorization thas been obto Interval Every 4 weeks a negative TB s are not met, rev            | Defer Until                                    | Duration  |
|               | **Please include H&P/ current medications list/ allerg  For Blood Transfusions, please ens  ia to Treat  Criteria to Treat  Verify that the patient has: 1) a negative hepatitis B screen of treatment 3) not received a live vaccine within the last 4 week   | ies, and ensure that mure that signed consertion.  Dose  or is hepatitis B immune 2 eks. If any of these criteria umentation not found, cor | Interval Every 4 weeks a negative TB s are not met, rev  | Defer Until status or adequate TB iew provider | Duration<br>Until<br>discont'd                  |
|               | **Please include H&P/ current medications list/ allerg  For Blood Transfusions, please ens  ia to Treat  Criteria to Treat  Verify that the patient has: 1) a negative hepatitis B screen of treatment 3) not received a live vaccine within the last 4 weed documentation that it is okay to proceed with infusion. If doc  | ies, and ensure that mure that signed consertion  Dose  or is hepatitis B immune 2 eks. If any of these criteria                            | ed authorization thas been obto Interval Every 4 weeks a negative TB s are not met, rev            | Defer Until                                    | <b>Duration</b> Until                           |
| □<br>Pre-M    | **Please include H&P/ current medications list/ allerg  For Blood Transfusions, please ens  ia to Treat  Criteria to Treat  Verify that the patient has: 1) a negative hepatitis B screen of treatment 3) not received a live vaccine within the last 4 weed documentation that it is okay to proceed with infusion. If documentations that it is okay to proceed with infusion. If documentations are considered to the constant of the const | Dose  or is hepatitis B immune 2 eks. If any of these criteria umentation not found, cor  | Interval Every 4 weeks a negative TB s are not met, rev ntact the provider                         | Defer Until status or adequate TB iew provider | Duration<br>Until<br>discont'd                  |
| □<br>Pre-M    | **Please include H&P/ current medications list/ allerg  For Blood Transfusions, please ens  ia to Treat  Criteria to Treat  Verify that the patient has: 1) a negative hepatitis B screen of treatment 3) not received a live vaccine within the last 4 weed documentation that it is okay to proceed with infusion. If documentations  dedications  acetaminophen (TYLENOL) tablet 650 mg  650 mg, Oral, Once   | Dose  or is hepatitis B immune 2 eks. If any of these criteria umentation not found, cor  | Interval Every 4 weeks a negative TB s are not met, rev ntact the provider                         | Defer Until status or adequate TB iew provider | Duration<br>Until<br>discont'd                  |
| Pre-M         | **Please include H&P/ current medications list/ allerg  For Blood Transfusions, please ensitia to Treat  Criteria to Treat  Verify that the patient has: 1) a negative hepatitis B screen of treatment 3) not received a live vaccine within the last 4 weed documentation that it is okay to proceed with infusion. If documentations  dedications  acetaminophen (TYLENOL) tablet 650 mg  650 mg, Oral, Once  Administer at least 30 mins prior to principal medication.  loratadine (CLARITIN) tablet 10 mg   | Dose  or is hepatitis B immune 2 eks. If any of these criteria umentation not found, cor  Dose  10 mg                                       | Interval Every 4 weeks are not met, revolutact the provider  Interval Every 4 weeks  Every 4 weeks | Defer Until status or adequate TB iew provider | Duration Until discont'd  Duration 2 treatments |

180 mg, Oral, Once

Order based on formulary availability. Administer at least 30 mins prior to principal medication.





## **GOLIMUMAB LOAD (SCHEDULE WEEKS 0,4)**

CDH 208-261 — Approved - Page 2 of 5

|    | ations   | Dose   | Interval  | Defer Until       | Duration                        |
|----|--|--|---|-------------------|---------------------------------|
| П  | golimumab (SIMPONI ARIA) 2 mg/kg in sodium   | 2 mg/kg  | Every 4   | Delei Olitii      | 2                               |
|    | chloride 0.9% 100 mL IVPB<br>2 mg/kg, Intravenous, for 30 Minutes, Once  | 2 mg/ng  | weeks   |                   | treatmen                        |
|    | loratadine (CLARITIN) tablet 10 mg   | 10 mg  | Every 4   |                   | 2                               |
|    | 10 mg Oral Open  |  | weeks   |                   | treatmen                        |
|    | 10 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins pr  | ior to principal me  | dication  |                   |                                 |
|    | fexofenadine (ALLEGRA) tablet 180 mg   | 180 mg   | Every 4   |                   | 2                               |
|    | lexorenaume (ALLEONA) tablet 100 mg  | 100 mg   | weeks   |                   | treatmen                        |
|    | 180 mg, Oral, Once   |  |   |                   |                                 |
|    | Order based on formulary availability. Administer at least 30 mins pr  | ior to principal me  | dication.   |                   |                                 |
|    |  |  |   |                   |                                 |
| s  |  |  |   |                   |                                 |
|    |  |  |   |                   |                                 |
| ,3 |  | Dose   | Interval  | Defer Until       | Duratio                         |
|    | Comprehensive metabolic panel  | Dose   | Interval<br>Once  | Defer Until       | 1                               |
|    |  |  | Once  |                   | 1                               |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat   |  | Once  |                   | 1                               |
|    |  |  | Once  |                   | 1                               |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST loratadine (CLARITIN) tablet 10 mg   | inine, Calcium, Alk  | Once  |                   | 1<br>treatme                    |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once   | inine, Calcium, Alb  | Once<br>bumin, Alkaline Pl<br>Once  |                   | 1<br>treatme                    |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once  Order based on formulary availability. Administer at least 30 mins pr  | inine, Calcium, Alt<br>10 mg<br>ior to principal me                                  | Once  Dumin, Alkaline Pl  Once  dication.                                       |                   | 1<br>treatme<br>1<br>treatme    |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once   | inine, Calcium, Alb  | Once<br>bumin, Alkaline Pl<br>Once  |                   | 1 treatme  1 treatme            |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins pr  fexofenadine (ALLEGRA) tablet 180 mg   | inine, Calcium, Alt<br>10 mg<br>ior to principal me                                  | Once  Dumin, Alkaline Pl  Once  dication.                                       |                   | 1 treatme  1 treatme            |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once  Order based on formulary availability. Administer at least 30 mins pr  | inine, Calcium, Alb<br>10 mg<br>ior to principal me<br>180 mg                        | Once bumin, Alkaline Pl Once bdication. Once                                    |                   | 1<br>treatme<br>1<br>treatme    |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once  Order based on formulary availability. Administer at least 30 mins pr  fexofenadine (ALLEGRA) tablet 180 mg  180 mg, Oral, Once  | inine, Calcium, Alb<br>10 mg<br>ior to principal me<br>180 mg                        | Once bumin, Alkaline Pl Once bdication. Once                                    |                   | 1<br>treatme<br>1<br>treatme    |
|    | consists of the following tests: Na, K, CI, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins profexofenadine (ALLEGRA) tablet 180 mg  180 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins professed on formulary availability. Administer at least 30 mins professed and differential | inine, Calcium, Alb<br>10 mg<br>ior to principal me<br>180 mg<br>ior to principal me | Once  Doumin, Alkaline Planting  Once  Idication.  Once  Idication.  Once  Once | hosphatase, Total | 1 treatme  1 treatme  1 treatme |
|    | consists of the following tests: Na, K, Cl, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins pr  fexofenadine (ALLEGRA) tablet 180 mg  180 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins pr   | inine, Calcium, Alb<br>10 mg<br>ior to principal me<br>180 mg<br>ior to principal me | Once  Doumin, Alkaline Planting  Once  Idication.  Once  Idication.  Once  Once | hosphatase, Total | 1 treatme  1 treatme  1 treatme |
|    | consists of the following tests: Na, K, CI, CO2, BUN, Glucose, Creat Bilirubin, Total Protein, ALT, and AST  loratadine (CLARITIN) tablet 10 mg  10 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins profexofenadine (ALLEGRA) tablet 180 mg  180 mg, Oral, Once Order based on formulary availability. Administer at least 30 mins professed on formulary availability. Administer at least 30 mins professed and differential | inine, Calcium, Alb<br>10 mg<br>ior to principal me<br>180 mg<br>ior to principal me | Once  Doumin, Alkaline Planting  Once  Idication.  Once  Idication.  Once  Once | hosphatase, Total | treatme<br>1<br>treatme         |

180 mg

Once

Once

treatment

treatment

Order based on formulary availability. Administer at least 30 mins prior to principal medication.


Order based on formulary availability. Administer at least 30 mins prior to principal medication.

No details available for preview

Sedimentation rate (ESR)

180 mg, Oral, Once

fexofenadine (ALLEGRA) tablet 180 mg





# **GOLIMUMAB LOAD (SCHEDULE WEEKS 0,4)**


CDH 208-261 - Approved - Page 3 of 5

Labs (continued)

|  | Dose            | Interval   | Defer Until | Duration       |
|--|-----------------|------------|-------------|----------------|
| Ioratadine (CLARITIN) tablet 10 mg                                       | 10 mg           | Once       |             | 1<br>treatment |
| 10 mg, Oral, Once  |                 |            |             |                |
| Order based on formulary availability. Administer at least 30 mins prior | to principal me | edication. |             |                |
| fexofenadine (ALLEGRA) tablet 180 mg                                     | 180 mg          | Once       |             | 1<br>treatment |
| 180 mg, Oral, Once   |                 |            |             |                |
| Order based on formulary availability. Administer at least 30 mins prior | to principal me | edication. |             |                |
| C-Reactive Protein   |                 | Once       |             | 1              |
|  |                 |            |             | treatment      |
| No details available for preview   |                 |            |             |                |
| loratadine (CLARITIN) tablet 10 mg                                       | 10 mg           | Once       |             | 1              |
|  |                 |            |             | treatment      |
| 10 mg, Oral, Once  |                 |            |             |                |
| Order based on formulary availability. Administer at least 30 mins prior | to principal me | edication. |             |                |
| fexofenadine (ALLEGRA) tablet 180 mg                                     | 180 mg          | Once       |             | 1<br>treatment |
| 180 mg, Oral, Once   |                 |            |             |                |
| Order based on formulary availability. Administer at least 30 mins prior | to principal me | edication. |             |                |

## **Catheter management**

|  | Dose             | Interval           | Defer Until           | Duration           |
|--|------------------|--------------------|-----------------------|--------------------|
| Line Access  |                  | PRN                |                       | Until<br>discont'd |
| Routine  |                  |                    |                       |                    |
| As needed. Until Specified. Insert peripheral IV, or access peripheral, or | or central vend  | ous access device, | to provide treatment. |                    |
| alteplase (CATHFLO) 1 mg/mL injection 2 mg                                 | 2 mg             | PRN                |                       | Until<br>discont'd |
| 2 mg, Intracatheter, As needed, line care                                  |                  |                    |                       |                    |
| For central venous access device requiring clearance. Administer per       | institutional gu | idelines. May repe | at once per lumen.    |                    |
| lidocaine-prilocaine (EMLA) cream  |                  | PRN                |                       | Until<br>discont'd |
| Topical, As needed, apply prior to the PIV insertion or port access        |                  |                    |                       |                    |
| heparin 100 units/mL flush 5 mL  | 5 mL             | PRN                |                       | Until<br>discont'd |
| 5 mL, Intravenous, As needed, Line care per institutional guidelines       |                  |                    |                       |                    |
| heparin 10 units/mL flush 3 mL   | 3 mL             | PRN                |                       | Until<br>discont'd |
| 3 mL, Intravenous, As needed, Line care per institutional guidelines       |                  |                    |                       |                    |
| heparin 10 units/mL flush 5 mL   | 5 mL             | PRN                |                       | Until<br>discont'd |
| 5 mL, Intravenous, As needed, line care, Line care per institutional gui   | delines          |                    |                       |                    |






Select a Mode of Therapy: Non-Rebreather

# GOLIMUMAB LOAD (SCHEDULE WEEKS 0,4)

CDH 208-261 - Approved - Page 4 of 5

|     |  | Dose   | Interval   | Defer Until   | Duratio                     |
|-----|--|--|--|---|-----------------------------|
|     | heparin 1000 units/mL flush 2 mL   | 2 mL   | PRN  |   | Until                       |
|     |  |  |  |   | discont                     |
|     | 2 mL, Intracatheter, As needed, APHERESIS LINE CARE ONLY per<br>FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THRO   |  |  |   |                             |
|     | sodium chloride (NS) 0.9 % syringe flush 3 mL  | 3 mL   | PRN  |   | Until                       |
|     | , ,  |  |  |   | discont                     |
|     | 3 mL, Intravenous, As needed, Line care per institutional guidelines   |  |  |   |                             |
|     | sodium chloride (NS) 0.9 % syringe flush 10 mL   | 10 mL  | PRN  |   | Until                       |
|     | 10 mL, Intravenous, As needed, line care, Line care per institutional  | auidelines   |  |   | discont                     |
| _   | ·  |  | PRN  |   | Until                       |
|     | sodium chloride (NS) 0.9 % syringe flush 20 mL   | 20 mL  | FKN  |   | discont                     |
|     | 20 mL, Intravenous, As needed, line care, Line care per institutional  | guidelines   |  |   | aisooiii                    |
|     | sodium chloride 0.9% infusion  | 20 mL/hr   | PRN  |   | Until                       |
|     |  |  |  |   | discont                     |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide   |  |  |   |                             |
|     | D5W infusion   | 20 mL/hr   | DDN  |   |                             |
|     | DOW IIII USIOII  | 20 ML/M  | PRN  |   | Until                       |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide   |  | PKN  |   |                             |
|     |  |  | Interval<br>PRN  | Defer Until   | discont  Duratio Until      |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  | treatment  | Interval   | Defer Until   | Duratic Until               |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throsoxygen saturation. Stop the infusion and treat with epinephrine FIRS oxygen as needed, monitor vital signs and proceed with administering.   | Dose  at swelling, wheez   | Interval<br>PRN<br>ing, respiratory d<br>and emergency p   | istress, or decreased<br>personnel, administer                  | Duratic Until               |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throsoxygen saturation. Stop the infusion and treat with epinephrine FIRS   | Dose  at swelling, wheez   | Interval<br>PRN<br>ing, respiratory d<br>and emergency p   | istress, or decreased<br>personnel, administer                  | Duratio<br>Until<br>discont |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throsoxygen saturation. Stop the infusion and treat with epinephrine FIRS oxygen as needed, monitor vital signs and proceed with administerin clinically indicated.  EPINEPHrine injection 0.3 mg   | Dose  at swelling, wheez T. Notify provider og adjunct HYPER .3 mg                                       | Interval PRN  ing, respiratory d and emergency p SENSITIVITY me  | istress, or decreased<br>personnel, administer<br>edications as | Duratio<br>Until<br>discont |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throsoxygen saturation. Stop the infusion and treat with epinephrine FIRS oxygen as needed, monitor vital signs and proceed with administering clinically indicated.  EPINEPHrine injection 0.3 mg  0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for   | Dose  at swelling, wheez T. Notify provider g adjunct HYPER .3 mg  | Interval PRN  ing, respiratory dependence processes proc | istress, or decreased<br>personnel, administer<br>edications as | Duratio<br>Until<br>discont |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throa oxygen saturation. Stop the infusion and treat with epinephrine FIRS oxygen as needed, monitor vital signs and proceed with administering clinically indicated.  EPINEPHrine injection 0.3 mg  0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine                                     | Dose  at swelling, wheez T. Notify provider og adjunct HYPER .3 mg or anaphylaxis. Ma 1:1000 is equivale | Interval PRN  ing, respiratory description of the second o | istress, or decreased<br>personnel, administer<br>edications as | Duratio<br>Until<br>discont |
| ]   | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throsoxygen saturation. Stop the infusion and treat with epinephrine FIRS oxygen as needed, monitor vital signs and proceed with administering clinically indicated.  EPINEPHrine injection 0.3 mg  0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for   | Dose  at swelling, wheez T. Notify provider g adjunct HYPER .3 mg  | Interval PRN  ing, respiratory dependence processes proc | istress, or decreased<br>personnel, administer<br>edications as | Duratio<br>Until<br>discont |
|     | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throa oxygen saturation. Stop the infusion and treat with epinephrine FIRS oxygen as needed, monitor vital signs and proceed with administering clinically indicated.  EPINEPHrine injection 0.3 mg  0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine                                     | Dose  at swelling, wheez T. Notify provider og adjunct HYPER .3 mg or anaphylaxis. Ma 1:1000 is equivale | Interval PRN  ing, respiratory description of the second o | istress, or decreased<br>personnel, administer<br>edications as | Duratio<br>Until<br>discont |
| erg | 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide  gency Medications/Anaphylaxis  Provider and Nurse Communication  Routine  Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throa oxygen saturation. Stop the infusion and treat with epinephrine FIRS oxygen as needed, monitor vital signs and proceed with administering clinically indicated.  EPINEPHrine injection 0.3 mg  0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine sodium chloride 0.9% bolus 1,000 mL | Dose  at swelling, wheez T. Notify provider og adjunct HYPER .3 mg or anaphylaxis. Ma 1:1000 is equivale | Interval PRN  ing, respiratory description of the second o | istress, or decreased<br>personnel, administer<br>edications as | Duratic<br>Until<br>discont |





# **GOLIMUMAB LOAD (SCHEDULE WEEKS 0,4)**

CDH 208-261 — Approved - Page 5 of 5

| ypers | sensitivity   |             |                    |                        |                                |
|-------|---|-------------|--------------------|------------------------|--------------------------------|
|       | Provider and Nurse Communication  | Dose        | Interval<br>PRN    | Defer Until            | Duration<br>Until<br>discont'd |
|       | Routine Treatment for mild-moderate infusion reaction: Stop the infusion, notify poxygen as needed, monitor vital signs and proceed with administering mreaction, refer to Emergency Medications section. |             |                    |                        |                                |
|       | albuterol (ACCUNEB) nebulizer solution 2.5 mg   | 2.5 mg      | PRN                |                        | Until<br>discont'd             |
|       | 2.5 mg, Nebulization, Once as needed, wheezing, shortness of breath   |             |                    |                        |                                |
|       | acetaminophen (TYLENOL) tablet 975 mg   | 975 mg      | PRN                |                        | Until<br>discont'd             |
|       | 975 mg, Oral, Once as needed, fever   |             |                    |                        |                                |
|       | diphenhydrAMINE (BENADRYL) injection 25 mg  | 25 mg       | PRN                |                        | Until<br>discont'd             |
|       | 25 mg, Intravenous, As needed, itching, hives. Begin with 25 mg. If patie mg  |             |                    | ninister additional 25 |                                |
|       | famotidine (PEPCID) injection 20 mg   | 20 mg       | PRN                |                        | Until<br>discont'd             |
|       | 20 mg, Intravenous, Once as needed, Adjunct treatment for mild-modera   | •           |                    | f: given as premed     |                                |
|       | cetirizine (ZyrTEC) tablet 10 mg  | 10 mg       | PRN                |                        | Until<br>discont'd             |
|       | 10 mg, Oral, Once as needed, Adjunct treatment for mild-moderate, or S HOLD IF: given fexofenadine.   | EVERE react | ion.               |                        |                                |
|       | fexofenadine (ALLEGRA) tablet 180 mg  | 180 mg      | PRN                |                        | Until<br>discont'd             |
|       | 180 mg, Oral, Once as needed, Adjunct treatment for mild-moderate, or HOLD IF: given cetirizine.  | SEVERE read | ction.             |                        | G.000                          |
|       | methylprednisolone sodium succinate (SOLU-Medrol) IV 40 mg 40 mg, Intravenous, Once as needed, Adjunct treatment for mild-modera  | _           | PRN<br>RE reaction |                        | Until<br>discont'd             |
|       | ondansetron (ZOFRAN) injection 4 mg   | 4 mg        | PRN                |                        | Until<br>discont'd             |
|       | 4 mg, Intravenous, As needed, nausea, vomiting, may repeat x 1 dose   |             |                    |                        |                                |
|       | meperidine (DEMEROL) injection 25 mg  | 25 mg       | PRN                |                        | Until<br>discont'd             |

25 mg, Intravenous, Once as needed, rigors

Contraindicated in patients receiving MAO inhibitors within 14 days. Caution in renal or hepatic impairment: Reduce dose since accumulation of meperidine and its active metabolite (normeperidine) may occur.